Thousands of children living with debilitating allergies could soon gain access to innovative daily tablet treatments after the National Institute for Health and Care Excellence recommended widening eligibility for two therapies designed to tackle the root cause of allergic reactions.
Under the draft recommendations, Acarizax will now be available to children aged 5 to 11 with severe house dust mite allergy, while Itulazax has been approved for young people aged 5 to 17 with birch tree pollen allergy.
More than 2,000 children across England are expected to benefit from the expanded access, offering relief for those whose symptoms have not responded adequately to conventional treatments.
Unlike standard medications that mainly manage symptoms, both Acarizax and Itulazax work through allergen immunotherapy. Patients take a soft tablet containing a small dose of the allergen each day, helping the immune system gradually build tolerance over time.
The treatments are taken daily for three years, with evidence showing they can significantly reduce allergy symptoms and lessen reliance on other medicines.
Allergic rhinitis affects thousands of children and young people, causing symptoms such as:
- Sneezing
- An itchy nose
- A blocked or runny nose
- Itchy, red and watery eyes
For some patients, the condition can be far more serious, leading to fatigue, facial swelling and disrupted sleep that impacts school attendance, concentration and overall quality of life.
The condition is considered persistent when symptoms occur for at least four days a week over a month and are not controlled by standard treatments.
Evidence reviewed by NICE's independent committee found that extending both treatments to younger children was more effective than standard treatment alone in reducing symptoms and decreasing the need for additional medication.
The decision reflects growing recognition of the long-term benefits of allergen immunotherapy for children living with severe and persistent allergies.
Following publication of final NICE guidance, NHS England is expected to make both treatments available within three months, providing a new treatment option for children and families struggling with difficult-to-manage allergies.
Healthcare leaders believe the expanded access could help improve quality of life for thousands of young patients while reducing the broader burden of allergy-related illness on NHS services.
Image credit: iStock
